Neola Medical

Hem
Sverige
Lund
Neola Medical

Our vision is to give preterm born infants a better start in life by continuous lung monitoring

Neola Medical AB (publ) has the potential to revolutionize neonatal care with Neola, a medical technology product that offers continuous lung monitoring and real-time alerts of life-threatening complications using a cutting-edge technology that measures lung volume and oxygen gas concentration. Neola has the potential to provide better care, fewer days in intensive care and healthier lives for preterm born infants. Founded in 2016 and headquartered in Lund, Sweden, Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care.

16/10/2025

📣 Neola Medical Strengthens Global IP Portfolio with New Patents Granted in both the U.S. and China for Medical Device Neola®

“Patent protection in both the U.S. and China secures a key part of our medical device in two of the world’s most significant healthcare markets. It supports our pathway toward U.S. market authorization and long-term global commercialization,” says CEO Hanna Sjöström.

💡 Read more in the press release here: https://www.neolamedical.com/mfn_news/neola-medical-strengthens-global-ip-portfolio-with-new-patents-granted-in-both-the-u-s-and-china-for-medical-device-neola/

01/10/2025

📣 Today we released the autumn edition of Neola Medical’s Investor Letter 2025

“Strengthening our leadership team, expanding our patent portfolio, and deepening our international network through Stanford Impact1 are all important steps as we advance toward market authorization and continue our mission to improve outcomes for preterm born babies,” says CEO Hanna Sjöström.

💡 Read the entire press release and the investor letter here: https://www.neolamedical.com/mfn_news/neola-medicals-ceo-highlights-recent-progress-in-autumn-2025-investor-letter/

25/09/2025

📣 Neola Medical strengthens leadership team with appointment of Clinical Director

“We are very pleased to welcome Eva Bondesson to Neola Medical’s leadership team. Her extensive experience in global clinical development, including collaboration with the U.S. FDA and other regulatory authorities, will be highly valuable as we advance through the clinical phase and prepare for our planned U.S. market authorization. With her strong expertise in lung physiology and proven track record in leading international studies, she brings an important complement to our team and to our mission of improving outcomes for preterm born babies,” says CEO Hanna Sjöström.

💡 Read more in the press release here: https://www.neolamedical.com/mfn_news/neola-medical-strengthens-leadership-team-with-appointment-of-clinical-director/

16/09/2025

🚀 CEO Hanna Sjöström invited as panelist at Stanford Impact1 CEO Summit in Austin, Texas 🇺🇸

“It is an honor to return to the Stanford Impact1 CEO Summit and to contribute to the important dialogue around board and investor relationships. As a Stanford Impact1 company, Neola Medical benefits greatly from the expertise and networks that this unique program provides. The exclusive CEO Summit is an invaluable forum to share our journey, connect with thought-leaders, and exchange perspectives on how to bring impactful innovations like Neola® to pediatric patients worldwide,” says CEO Hanna Sjöström.

💡Learn more and read the entire article about the exclusive particiapation at Stanford Impact1 here: https://www.neolamedical.com/mfn_news/ceo-hanna-sjostrom-invited-as-panelist-at-stanford-impact1-ceo-summit-in-austin-texas/

💡Read the press release about the Stanford Impact1 program announcement in 2023 here: https://www.neolamedical.com/mfn_news/stanford-utser-neola-medicals-medicintekniska-produkt-till-en-viktig-innovation-for-neonatalvarden-och-ger-bolaget-stod-till-marknadsetablering-genom-exklusiva-programmet-impact1/

🎥 Watch the welcome speech to the Stanford Impact1 program in 2023 by founding director, James Wall, here: https://www.linkedin.com/feed/update/urn:li:activity:7119952940315926529

10/09/2025

📣 Neola Medical granted European patent enabling lung monitoring beyond preterm born babies 🇪🇺

“Europe, together with the U.S. and China, represents one of our most important markets. This granted patent not only strengthens our protection of the core technology but also opens opportunities to apply our innovation in additional patient groups. That represents an exciting future growth potential for Neola Medical,” says CEO Hanna Sjöström.

💡 Read more in the press release here: https://www.neolamedical.com/mfn_news/neola-medical-granted-european-patent-enabling-lung-monitoring-beyond-preterm-born-babies/

27/08/2025

🌟 Innovation, Purpose, and Growth: Hanna Sjöström in the Spotlight with PRO TEMPORE🌟

In a new Spotlight interview with PRO TEMPORE, Hanna Sjöström, CEO of Neola Medical, shares her career journey, perspectives on leadership in times of change, and why she believes in the powerful combination of technology and purpose.

With experience from global giants such as L’Oréal and Coca-Cola, as well as agile medtech start-ups, Hanna Sjöström has found her place at the intersection of innovation and societal impact. As CEO of Neola Medical, she leads a company developing technology to continuously monitor the lungs of preterm born babies, with the goal of enabling earlier detection of complications. In the interview, she talks about steering a listed company through capital raising, regulatory milestones, and international expansion.

Beyond Neola Medical, Hanna Sjöström serves on several boards within the Life Science sector and shares her insights on leadership, perseverance, and what fuels her energy outside of work.

💡 Read the full interview in Swedish here: https://lnkd.in/dXi7q5EC

26/08/2025

🚀 Redeye Interview: Neola Medical Q2 2025 with CEO Hanna Sjöström

In a new interview with Redeye’s Gustaf Meyer, CEO Hanna Sjöström reflects on Q2 achievements and the road ahead. Redeye also provided a research update, raising their fair value range, now with a base case of SEK 3.3 (3.2).

🎥 Watch the full interview here: https://vimeo.com/user103789251/review/1112883265/88aaf27cc8

💡 Access the research update and additional insights from Redeye here: https://www.redeye.se/company/neola-medical

26/08/2025

🌟 Did you miss Neola Medical’s Q2 report presentation? 🌟

Catch up on Neola Medical’s Q2 highlights, including the successful enrollment of the first preterm born baby in the clinical pilot study in Sweden and advancing preparations for the pivotal U.S. clinical study 🇺🇸

CEO Hanna Sjöström shares insights into these key milestones, recent patent progress, and our strengthened U.S. presence as we continue to advance toward FDA market authorization. CFO David Folkesson presents the financial results for Q2 2025.

🎥 Watch the full report presentation and stay for the Q&A session. Tune in here: https://www.youtube.com/watch?v=CJwJ4gyVyPY

25/08/2025

📣 Neola Medical today released the Q2 report of 2025! 📘🫁

Neola Medical Q2 Report 2025 – First U.S. Clinical Study Site Agreement Signed, Key Step in Regulatory Path to Market Authorization 🇺🇸

“Advancing preparations for our pivotal U.S. clinical study with the signing of an agreement at a key site, a milestone that strengthens our regulatory pathway toward FDA market authorization.”, says CEO Hanna Sjöström

💡 Read the entire press release and the report at our website: https://www.neolamedical.com/mfn_news/neola-medical-q2-report-2025-first-u-s-clinical-study-site-agreement-signed-key-step-in-regulatory-path-to-market-authorization/

18/08/2025

📣 We hereby invite you to presentation of our Q2 report of 2025!

The report presentation will be held online as a webcast hosted by Finwire. The Q2-report will be published the same day in the morning.

🗓️ August 25, 2025, at 11:30 CET (11.30)

🎥 Watch the presentation here: https://www.finwire.tv/webcast/neola-medical/q2-2025/ where you also can type in questions in advance and during the presentation that we will be answering live during the Q&A after the presentation. 📨

💡Read more in the press release here: https://www.neolamedical.com/mfn_news/neola-medical-invites-to-presentation-of-the-q2-report-2025/

17/06/2025

💡Help Us Improve – Take the Neola Medical Communication Survey 2025 💬

Neola Medical invites you to take a brief, approximately 5-minute survey to share your thoughts on how we communicate. Your input will help us improve our updates, website, and investor letters so they better reflect your interests and needs.

The survey is completely anonymous, open for two weeks, and all data is handled in accordance with GDPR.

👉 Take the survey here: https://www.survio.com/survey/d/NeolaMedicalCommunicationSurvey2025

Thank you for helping us grow and improve! ✨

16/06/2025

📣 Today we released the summer edition of Neola Medical’s Investor Letter 2025

“The first real-world use of Neola® to monitor the lungs of a baby, in our ongoing clinical pilot study in Sweden, marks a historic milestone for the company. At the same time, we are making important progress in preparing our pivotal clinical study in the U.S., which will support the foundation of our planned FDA application for market authorization,” says CEO Hanna Sjöström.

💡 Read the entire press release and the investor letter here: https://www.neolamedical.com/mfn_news/neola-medicals-ceo-shares-clinical-progress-and-recent-milestones-in-summer-2025-investor-letter/

Adress

Scheelevägen 27
Lund
22363

Webbplats

https://www.neolamedical.com/

Aviseringar

Var den första att veta och låt oss skicka ett mail när Neola Medical postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Praktiken

Skicka ett meddelande till Neola Medical:

Genvägar

Vill du placera din praktik längst upp i Klinik-listan i Lund?

Dela

Typ

Medicin och hälsa